These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17664462)

  • 21. HER2-positive breast cancer: current treatment strategies.
    Perez EA; Baweja M
    Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
    [No Abstract]   [Full Text] [Related]  

  • 22. A National Quality Assurance program for breast immunohistochemistry: an Italian perspective.
    Guadagno E; De Rosa G; Nappi O
    Pathologica; 2018 Sep; 110(2):83-91. PubMed ID: 30546143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
    Aoyama K; Kamio T; Nishikawa T; Kameoka S
    Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Egervari K; Szollosi Z; Nemes Z
    Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):510-1. PubMed ID: 18580496
    [No Abstract]   [Full Text] [Related]  

  • 25. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
    Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
    Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
    Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
    Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 testing and correlation with efficacy of trastuzumab therapy.
    Konecny G; Slamon DJ
    Oncology (Williston Park); 2002 Nov; 16(11):1576, 1578. PubMed ID: 12469932
    [No Abstract]   [Full Text] [Related]  

  • 28. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
    Fujita T; Doihara H; Kawasaki K; Takabatake D; Takahashi H; Washio K; Tsukuda K; Ogasawara Y; Shimizu N
    Br J Cancer; 2006 Jan; 94(2):247-52. PubMed ID: 16404430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of clinical and non-clinical factors on the choice of HER2 test for breast cancer.
    Ashok M; Griffin P; Halpern M
    Cancer Invest; 2010 Aug; 28(7):735-42. PubMed ID: 20590449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The quality of Her-2/Neu predictive immunohistochemistry: something FISHy?
    Tubbs RR; Stoler MH
    Mod Pathol; 2000 Jan; 13(1):1-3. PubMed ID: 10658903
    [No Abstract]   [Full Text] [Related]  

  • 32. Trastuzumab administration associated with change in HER2 status.
    Dawood S; Resetkova E; Gonzalez-Angulo AM
    Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of trastuzumab in the therapy of breast cancer].
    Riemer AB; Zielinski CC
    Ther Umsch; 2008 Apr; 65(4):217-22. PubMed ID: 18622914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.
    Umemura S; Osamura RY; Akiyama F; Honma K; Kurosumi M; Sasano H; Toyoshima S; Tsuda H; Rüschoff J; Sakamoto G
    Am J Clin Pathol; 2008 Dec; 130(6):883-91. PubMed ID: 19019764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.
    Kell MR; Power CP
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293849
    [No Abstract]   [Full Text] [Related]  

  • 36. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
    Layfield LJ; Willmore-Payne C; Isom G; Holden JA
    Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Assessment of HER2 status in breast cancer].
    Penault-Llorca F; Cayre A
    Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
    Chang HJ; Han SW; Oh DY; Im SA; Jeon YK; Park IA; Han W; Noh DY; Bang YJ; Kim TY
    Jpn J Clin Oncol; 2011 May; 41(5):593-9. PubMed ID: 21406492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.